Uni-Bio Science H1 revenue falls 12% on pricing changes

Uni-Bio Science

26/08/2026 11:18

Overview
Hong Kong-listed biopharma firm's H1 2026 revenue fell 12% yr/yr amid pricing adjustments
Net profit dropped 59% as R+D and commercialization investments rose
Company remained profitable, driven by strong Bogutai sales and operational resilience

Outlook
Uni-Bio expects FDA approval for Bogutai in the U.S. in 2027
Company expects Isavuconazonium sulfate capsules to receive China marketing approval in Q1 2027
Uni-Bio plans commercial launch of single-dose EGF ophthalmic product by end of 2027

Result Drivers
PRICING ADJUSTMENTS - Revenue was impacted by repricing of Pinup after VBP renewal, expansion of GeneTime hospital access, and VAT rate increase for biological products
BOGUTAI SALES GROWTH - Strong sales volume expansion of Bogutai drove revenue and operating leverage
INCREASED INVESTMENT - Higher R+D and commercialization spending contributed to earnings compression

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
HK$273.8 mln
 

Reuters Recommended Reads
Aug 25 - China's Innovent Biologics H1 revenue, profit rise on strong product sales
Aug 26 - China's Hansoh Pharma H1 revenue rises, driven by innovative medicines segment
Aug 24 - China's RemeGen H1 revenue soars on drug sales, AbbVie deal

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-26/05a90d55-fc25-434b-8585-00c8c837ffcf.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)